Quantel launches LacryDiag dry eye diagnosis device

At the World Ophthalmology Congress in Barcelona, Spain, Quantel Medical launched the LacryDiag ocular surface analyzer for the diagnosis of dry eye.

Approved by the FDA and CE marked, the device analyzes the three tear film layers with four non-contact exams, according to a company press release.

“Dry eye is a real public health problem, but the symptoms are often misunderstood. As a multifactorial pathology that results from damage to the tear film, this pathology is often underdiagnosed and underestimated,” Jean-Marc Gendre, CEO of Quantel Medical, said in the release. “With LacryDiag, ophthalmologists are now able to diagnosis in a few minutes the three tear film layers to select a personalized treatment for the patient.”

At the World Ophthalmology Congress in Barcelona, Spain, Quantel Medical launched the LacryDiag ocular surface analyzer for the diagnosis of dry eye.

Approved by the FDA and CE marked, the device analyzes the three tear film layers with four non-contact exams, according to a company press release.

“Dry eye is a real public health problem, but the symptoms are often misunderstood. As a multifactorial pathology that results from damage to the tear film, this pathology is often underdiagnosed and underestimated,” Jean-Marc Gendre, CEO of Quantel Medical, said in the release. “With LacryDiag, ophthalmologists are now able to diagnosis in a few minutes the three tear film layers to select a personalized treatment for the patient.”